Lee DW, Barrett DM, Mackall C, Orentas R, Grupp SA. The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer. Clin Cancer Res. 2012;18(10):2780–90.
Google Scholar
Johnson LA, June CH. Driving gene-engineered T cell immunotherapy of cancer. Cell Res. 2017;27(1):38–58.
Google Scholar
Rouce RH, Sharma S, Huynh M, Heslop HE. Recent advances in T-cell immunotherapy for haematological malignancies. Br J Haematol. 2017;176(5):688–704.
Google Scholar
June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379(1):64–73.
Google Scholar
Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119(12):2709–20.
Google Scholar
Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188–95.
Google Scholar
Teachey DT, Lacey SF, Shaw PA, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016;6(6):664–79.
Google Scholar
Brudno JN, Maric I, Hartman SD, et al. T cells genetically modified to express an Anti-B-Cell maturation antigen chimeric antigen receptor cause remissions of Poor-Prognosis relapsed multiple myeloma. J Clin Oncol. 2018;36(22):2267–80.
Google Scholar
Fitzgerald JC, Weiss SL, Maude SL, et al. Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit Care Med. 2017;45(2):e124–31.
Google Scholar
Trepo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet. 2014;384(9959):2053–63.
Google Scholar
Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2095–128.
Google Scholar
Shi Y, Yang Y, Hu YT, et al. Acute-on-chronic liver failure precipitated by hepatic injury is distinct from that precipitated by extrahepatic insults. Hepatology. 2015;62(1):232–42.
Google Scholar
Li H, Chen LY, Zhang NN, et al. Characteristics, diagnosis and prognosis of Acute-on-Chronic liver failure in cirrhosis associated to hepatitis B. Sci Rep. 2016;6:25487.
Google Scholar
Zhang YY, Meng ZJ. Definition and classification of acute-on-chronic liver diseases. World J Clin Cases. 2022;10(15):4717–25.
Google Scholar
Seto WK, Lai CL, Yuen MF. Acute-on-chronic liver failure in chronic hepatitis B. J Gastroenterol Hepatol. 2012;27(4):662–9.
Google Scholar
Zhao RH, Shi Y, Zhao H, Wu W, Sheng JF. Acute-on-chronic liver failure in chronic hepatitis B: an update. Expert Rev Gastroenterol Hepatol. 2018;12(4):341–50.
Google Scholar
Wang FS, Fan JG, Zhang Z, Gao B, Wang HY. The global burden of liver disease: the major impact of China. Hepatology. 2014;60(6):2099–108.
Google Scholar
Wu W, Yan H, Zhao H, et al. Characteristics of systemic inflammation in hepatitis B-precipitated ACLF: differentiate it from No-ACLF. Liver Int. 2018;38(2):248–57.
Google Scholar
Sarin SK, Choudhury A, Sharma MK, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int. 2019;13(4):353–90.
Google Scholar
EASL Clinical Practice. Guidelines on acute-on-chronic liver failure. J Hepatol. 2023;79(2):461–91.
Liver F, Artificial Liver Group CS, o. I. D. CMA, Severe Liver D, Artificial Liver Group CS. o. H. C. M. A. Guideline for diagnosis and treatment of liver failure. Zhonghua Gan Zang Bing Za Zhi. 2019;27(1):18–26.
Wu TZ, Li J, Shao L, et al. Development of diagnostic criteria and a prognostic score for hepatitis B virus -related acute -on – chronic liver failure. Gut. 2018;67(12):2181–91.
Google Scholar
Li J, Liang X, Jiang J. PBMC transcriptomics identifies immune-metabolism disorder during the development of. HBV-ACLF Gut. 2022;71(1):163–75.
Google Scholar
Fabri A, Kandara K, Coudereau R, et al. Characterization of Circulating IL-10-Producing cells in septic shock patients: A proof of concept study. Front Immunol. 2020;11:615009.
Google Scholar
Hyodo N, Nakamura I, Imawari M. Hepatitis B core antigen stimulates interleukin-10 secretion by both T cells and monocytes from peripheral blood of patients with chronic hepatitis B virus infection. Clin Exp Immunol. 2004;135(3):462–6.
Google Scholar
Lan T, Chang L, Wu L, Yuan YF. IL-6 plays a crucial role in HBV infection. J Clin Transl Hepatol. 2015;3(4):271–6.
Google Scholar
ZHANG ZHOUC, HE T T N, et al. High levels of serum interleukin-6 increase mortality of hepatitis B virus-associated acute-on-chronic liver failure[J]. World J Gastroenterol. 2020;26(30):4479–88.
Google Scholar
Wu Z-B, Zheng Y-B, Gao Z-L et al. Plasma Interleukin-6 level: A potential prognostic Indicator of emergent HBV-Associated ACLF. Can J Gastroenterol Hepatol 2021;11:20215545181.
Wu ZB, Zheng YB, Wang K, et al. Plasma Interleukin-6 level: A potential prognostic Indicator of emergent HBV-Associated ACLF. Can J Gastroenterol Hepatol. 2021;2021:5545181.
Google Scholar
Wei Wu H-D. Characteristics of systemic inflammation in hepatitis B-precipitated ACLF: differentiate it from No-ACLF. Liver Int. 2018;38(2):248–57.
Google Scholar
Zhu B, Gao F, Zhang Q, Wang X, et al. Serum cytokine and chemokine profiles and disease prognosis in hepatitis B virus-related acute-on-chronic liver failure. Front Immunol. 2023;14:1133656.
Google Scholar
Wu Z B Wangk, Ye Y N et al. Plasma Interleukin-10: a likely predictive marker for hepatitis b virus-related acute-on-chronic liver failure[J]. Hepat Mon 2014;14(7):e19370.
GARG V, GARG H. Granulocyte colony-stimulating factor mobilizes CD34 (+)cells and improves survival of patients with acute – on – chronic liver failure. Gastroenterology. 2012;142(3):505–12. e1.
Google Scholar
Schwabe RF, Luedde T. Apoptosis and necroptosis in the liver: a matter of life and death. Nat Rev Gastroenterol Hepatol. 2018;15:738–52.
Google Scholar
Park JJ, Wong DK, Wahed AS, et al. Hepatitis B virus-specific and global T-cell dysfunction in chronic hepatitis B. Gastroenterology. 2016;150(3):684–e6955.
Google Scholar
Gao S. Joshi ss,osiowy c,et al.chronic hepatitis B carriers with acute on chronic liver failure show increased HBV surface gene mutations, including immune escape variants. Virol J. 2017;14(1):203.
Google Scholar
Li J, Chen X, Zhou XP, et al. Defining the molecular basis of hepatitis B virus-related acute-on-chronic liver failure by transcriptome sequencing of patient peripheral blood mononuclearcells. Hepatology. 2018;68:191A.
Abraham E, Singer M. Mechanisms of sepsis-induced organ dysfunction. Crit Care Med. 2007;35(10):2408–16.
Google Scholar
Szabo G, Petrasek J. Inflammasome activation and function in liver disease. Nat Rev Gastroenterol Hepatol. 2015;12(7):387–400.
Google Scholar
Tsung A, Sahai R, Tanaka H, et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med. 2005;201(7):1135–43.
Google Scholar
Blazka M, Wilmer J, Holladay S, Wilson R, Luster M. Role of Proinflammatory cytokines in acetaminophen hepatotoxicity. Toxicol Appl Pharmacol. 1995;133(1):43–52.
Google Scholar
Ishida Y, Kondo T, Kimura A, Tsuneyama K, Takayasu T, Mukaida N. Opposite roles of neutrophils and macrophages in the pathogenesis of acetaminopheninduced acute liver injury. Eur J Immunol. 2006;36(4):1028–38.
Google Scholar
Arroyo V, Moreau R, Jalan R, et al. Acute-on-chronic liver failure: A new syndrome that will re-classify cirrhosis. J Hepatol. 2015;62(1 Suppl):s131–43.
Google Scholar
Hernaez R, Sola E, Moreau R, et al. Acute-on-chronic liver failure: an update. Gut. 2017;66(3):541–53.
Google Scholar
Yu X, Yang F, Zhang J,et, Al. BTLA contributes to acute-on-chronic liver failure infection and mortality through CD4 + T-cell exhaustion. Nat Commun. 2024;15(1):1835.
Google Scholar
ANTONIADES C G, BERRY P A, WENDON JA, et al. The importance of immune dysfunction in determining outcome in acute liver failure[J]. J Hepatol. 2008;49(5):845–61.
Google Scholar
ARROYO V, ANGELI P, MOREAU R, et al. The systemic inflammation hypothesis: towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis[J]. J Hepatol. 2021;74(3):670–85.
Google Scholar
Yao Z, Painter SL, Fanslow WC, Ulrich D, Macduff BM, Spriggs MK, Armitage RJ. Human IL-17: a novel cytokine derived from T cells. J Immunol. 1995b;155:5483–6.
Google Scholar
Bai Y, Zhou R, Fan J, et al. A novel bifunctional fusion protein (Anti-IL-17A-sST2) protects against acute liver failure, modulating the TLR4/MyD88 pathway and NLRP3 inflammasome activation. Biomedicines. 2024;12(5):1118.
Google Scholar
Tan NH, Chen B, Du S, et al. Treg/Th17 cell balance in patients with hepatitis B Virus-Related Acute-on-Chronic liver failure at different disease stages. Biomed Res Int. 2021;2021:9140602.
Google Scholar
Stoop JN, van der Molen RG, Janssen HL, et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology. 2005;41(4):771–8.
Google Scholar
Liu GL, Zhou XL, Tao P. The role of Th17 / Treg cell balance in the clinical outcome of hepatitis B virus -associated acute-on-chronic liver failure. Immunol J. 2014;30(7):623–7.
Zhang H, Huang LX, Chen ZX, et al. Effect of CD4 (+) CD25(+)Foxp3 (+)regulatory T cells on acute -on-chronic liver failure caused by hepatitis B infection. J Southeast Univ (Med Sci Edi). 2011;30(2):315–8.
Shah D, Soper B, Shopland L. Cytokine release syndrome and cancer immunotherapies – historical challenges and promising futures. Front Immunol. 2023;14:1190379.
Google Scholar
Norelli M, Camisa B, Barbiera G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24(6):739–48.
Google Scholar
Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 Blockade. Nat Med. 2018;24(6):731–8.
Google Scholar
Xie YQ, Wenes M, Wang Y, Gao M, Hu X, Romero P et al. IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases. Nat Biotechnol. 2024;42(11):1693–1704.
Guo H, Wang H, Yang H, et al. Metabolic reprogramming of terminally exhausted CD8(+) T cells by IL-10 enhances anti-tumor immunity. Nat Immunol. 2021;22:746–56.
Google Scholar
Huang YW, Wang HP. From suppressor to enhancer: IL-10’s alternative role in CAR-T cell therapies against solid tumors. Cell Stem Cell. 2024;31(3):285–7.
Google Scholar